

Implementation

Abrams EM, Erdle SC, Cameron SB, Soller L, Chan ES. How to incorporate oral immunotherapy into your clinical practice. *Current allergy and asthma reports*. 2021 Apr;21(4):30.

<https://link.springer.com/article/10.1007/s11882-021-01009-8>

- Review article summarizing OIT literature as well as the Canadian Society for Allergy and Clinical Immunology (CSACI) OIT guidelines with clinical vignettes

Leonard SA, Laubach S, Wang J. Integrating oral immunotherapy into clinical practice. *Journal of Allergy and Clinical Immunology*. 2021 Jan 1;147(1):1-3.

<https://www.sciencedirect.com/science/article/pii/S0091674920316274>

- Review and previous continuous assessment program article for the ABAI centered on implementation of OIT in the clinical setting

Outcome Considerations

Mack DP, Greenhawt M, Turner PJ, Wasserman RL, Hanna MA, Shaker M, Hughes SW, Del Río PR. Information needs of patients considering oral immunotherapy for food allergy. *Clinical & Experimental Allergy*. 2022 Dec;52(12):1391-402.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cea.14225>

- Review article highlighting important topics of discussion during initial consultation for oral immunotherapy

Lloyd M, Patel N, Munblit D, Tang ML. Endpoints and outcomes following immunotherapy for food allergy: What is meaningful for patients?. *The Journal of Allergy and Clinical Immunology: In Practice*. 2023 Feb 1.

<https://www.sciencedirect.com/science/article/pii/S2213219823001198>

- Review article discussing limitations of current outcome measures in OIT trials and considerations on how to communicate these to families

Major Research Articles

PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. *New England Journal of Medicine*. 2018 Nov 22;379(21):1991-2001.

<https://www.nejm.org/doi/full/10.1056/nejmoa1812856>

- Phase III clinical trial of Palforzia

Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, Herbert M. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. *The Journal of Allergy and Clinical Immunology: In Practice*. 2019 Feb 1;7(2):418-26.

<https://www.sciencedirect.com/science/article/pii/S2213219818303453>

- Large real-world cohort of peanut oral immunotherapy

Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, Scurlock AM, Chinthrajah S, Wang J, Pesek RD, Sindher SB. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. *The Lancet*. 2022 Jan 22;399(10322):359-71.

[https://www.thelancet.com/article/S0140-6736\(21\)02390-4/abstract](https://www.thelancet.com/article/S0140-6736(21)02390-4/abstract)

- Randomized control trial of peanut oral immunotherapy in toddlers with an additional arm examining food allergy remission

Palforzia

Palforzia package insert: <https://www.fda.gov/media/134838/download>

Patient information

Patient-facing resources from the ACAAI: <https://acaai.org/resources/peanut-oral-immunotherapy-oit/>